Latest News

SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV

© Synaffix


by tg

Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.

Lonza's centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO Biotech owned by Polish PPF Group. 

Under the terms of the agreement, SOTIO will gain access to Synaffix’s ADC technologies, GlycoConnect™, HydraSpace™ and toxSYN™ linker-payloads, in an initial ADC program with the option to expand research and commercial licenses into two additional programmess at a later date. 

According to the contract, Synaffix will be eligible to receive up to US$740m in payments spanning signature, target nomination and milestone payments plus additional royalties on commercial sales. SOTIO will be responsible for the research, development, and commercialisation of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies

UK boosts AMR defenses with £30m PACE initiative

By bringing together funding, resources, and partnerships from its three notable partners Innovate UK, LifeArc, and Medicines Discovery Catapult...

Xlife Sciences AG acquires 20% stake in 4D Lifetec AG

Spain set to unveil the potential of the biologisation of medicine and food production

At BioSpain 2023, several panels discussed the Spanish EU Presidency's goal of setting the course for the internationally competitive use of...

German company aims for the first EU approval for cell-cultured meat

The Cultivated B (Heidelberg, Germany) is the first company in the world to pre-register a partially cell-based meat product with the European Food...

Memo Therapeutics AG raises CHF25m

The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

Abingworth raises $356m for new CCD fund

London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

AMR: Partnership set to improve in vivo antibiotics testing

The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack...